ClinicalTrials.gg
TerminatedNCT01838044Updated Jan 28, 2021Results posted

Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Monotherapy, in Patients With Chronic Low Back Pain Having a Neuropathic Component

A Phase 4 interventional study of pregabalin and celecoxib and Placebo and celecoxib in Chronic Low Back Pain With a Neuropathic Component, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Terminated at 30 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Why this study was terminated
Recruitment terminated on 3Apr2015 due to slow recruitment rate and lack of operational feasibility. Study was not terminated for reasons of safety/efficacy.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Low Back Pain with a site in Mexico — 2 open to participants now, 2 under way, none of them phase 3. Low Back Pain · Mexico.

Started
2013
the only one that year
Phase 4
2 of 11
none open now
Registered
4th of 11
by date
Lead sponsor
1 of 11
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 11 studies in Low Back Pain with a site in Mexico, this one is the only one that started in 2013, is one of 2 in phase 4, and was the 4th registered.

Low Back Pain

2,926 studies on the registry are indexed under Low Back Pain; 579 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

2 of the 11 studies in Low Back Pain with a site in Mexico are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 92 (28%) set no upper age limit and 210 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Low Back Pain with a site in Mexico, or all of them as a file.
02

Study summary

The purpose of this study is to determine if treatment with celecoxib and pregabalin together would prove to be more effective in relief of pain than treatment with celecoxib alone in people who have chronic low back pain with a probable neuropathic component.

Read the detailed description

The primary objective is to evaluate the efficacy of the concomitant use of pregabalin and celecoxib compared with celecoxib monotherapy for the symptomatic relief of pain in patients with chronic low back pain with a probable neuropathic component.

The secondary objectives are:

  • Demonstrate the additional benefit of adding pregabalin to celecoxib monotherapy.
  • To evaluate the concomitant use of pregabalin and celecoxib compared to celecoxib monotherapy in a set of patient reported measures (sleep, depression, anxiety, impact of pain in daily functions, patient's global impression of change and patient's perception of the treatment).
  • To evaluate the safety and tolerability of celecoxib and of the concomitant administration of pregabalin and celecoxib.
03

Conditions studied

  • Chronic Low Back Pain With a Neuropathic Component

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have Chronic low back pain with high probability of a significant neuropathic component for 4 years or less (but no less than 3 months)
  • Subjects must be in generally good health, except for the presence of chronic low back pain with a neuropathic component.
  • Subjects must be literate and have the ability (unaided) to understand and use the interactive voice response system (IVRS), have daily access to a telephone or the internet in order to complete the IVRS assessments each day, perform telephone or web visits and complete all required assessments/forms

Exclusion criteria

Exclusion Criteria:

  • Subjects with past history of surgery for chronic low back pain.
  • Subjects with past history of failure on pregabalin treatment and/or intolerance associated with pregabalin or gabapentin.
  • Subjects with past history of intolerance associated with celecoxib or known to celecoxib.
  • Patients with anticipated need for treatment with opioid analgesics, anti-epileptic medications, SNRI antidepressants or tricyclic antidepressants to alleviate pain during the course of the study.
  • Patients with chronic low back pain with a neuropathic component for more than 4 years.
  • Patients with neurologic disorders unrelated to low back pain that may confuse or confound the assessment of neuropathic pain (eg, primary or secondary nerve diseases).
  • Subjects considered at risk of suicide or self-harm based on investigator judgment and/or details of a risk assessment.
  • Use of prohibited medications in the absence of appropriate .
  • Patients with any severe pain associated with conditions other than chronic low back pain with a neuropathic component that may confound the assessment or self-evaluation of the pain due to chronic low back pain.
  • Patients with diabetes with poor glycemic control ( >8%).
  • Patients with any or unstable medical or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, would compromise participation in the study
  • Patients who have participated in any previous clinical trial for pregabalin or have participated in 2 or more previous clinical trials for pain related to chronic low back pain.
  • Patients who are likely to require surgery during the course of the study (except minor surgery, eg, for skin conditions)
  • Patients with a history of Substance Abuse as defined by diagnostic criteria
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Arm A

    The group of patients who are randomized to receive concomitant treatment of pregabalin and celecoxib during the first study period.

    Drug: pregabalin and celecoxib

  • Other
    Arm B

    The group of patients who are randomized to receive celecoxib monotherapy during the first study period.

    Drug: Placebo and celecoxib

Interventions

  • Drugpregabalin and celecoxib

    Drug pages: Pregabalin · Celecoxib

    During the first study period subjects in Arm A will be administered a daily fixed dose of celecoxib 200 mg once daily and pregabalin 150 mg (75 mg BID) for one week (during Week 0) followed by pregabalin 300 mg (150 mg BID) daily for the remaining 4 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily. All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment.

  • DrugPlacebo and celecoxib

    Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily. All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Weekly Mean Pain Numeric Rating Scale (NRS) Score at Week 5 (ie, Visit 4) Compared Between the Two Study Arms

    The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.

    Time frame: Baseline and Week 5

Secondary outcomes

  1. Change in the Weekly Mean Pain NRS Score in Arm B, Compared Between Week 5 (Visit 4) and Week 10 (Visit 6).

    The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.

    Time frame: Week 5 and Week 10

  2. Change From Baseline in the Weekly Mean Pain NRS Score at Week 10 (Visit 6) Compared Between the Two Study Arms

    The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.

    Time frame: Baseline and Week 10

  3. Change From Baseline in Benefit, Satisfaction, and Willingness to Continue Measure Scores Compared Between Arms at Week 5 (Visit 4) and at Week 10 (Visit 6)

    The BSW consists of 3, single-item measures designed to capture the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy. The BSW was administered by the investigator or designated site personnel in the local language as a standardized interview during the follow-up visits. The BSW can potentially be self-administered; however, this method of administration has not been tested. Participants completed this questionnaire at Visit 4 and Visit 6.

    Time frame: Week 5 and Week 10

  4. Patient Global Impression of Change (PGIC) Compared Between Arms at Week 5 (Visit 4) and at Week 10 (Visit 6)

    The PGIC is a single-item, self-rated instrument that measures change in the patient's overall status since starting study medication on a scale from 1 (very much improved) to 7 (very much worse), where lower scores indicate greater improvement. This scale was administered at Visit 4 and Visit 6.

    Time frame: Week 5 and Week 10

  5. Percentage of Participants With PGIC for Each Arm Compared at Week 5 (Visit 4) and at Week 10 (Visit 6)

    The PGIC is a single-item, self-rated instrument that measures change in the patient's overall status since starting study medication on a scale from 1 (very much improved) to 7 (very much worse), where lower scores indicate greater improvement. This scale was administered at Visit 4 and Visit 6.

    Time frame: Week 5 and Week 10

  6. Change From Baseline in Weekly Mean of Daily Sleep Interference Rating Scale (SIRS) Compared Between Arms at Week 5 (Visit 4) and at Week 10 (Visit 6)

    The Daily Sleep Interference Rating Scale (SIRS) consists of an 11-point NRS ranging from 0 ("pain does not interfere with sleep") to 10 ("pain completely interferes with sleep" \[unable to sleep due to pain\]). Participants described how pain had interfered with their sleep during the past 24 hours: Select the number that best describes how your pain has interfered with your sleep during the past 24 hours on a scale from 0 to 10 where 0 represents 'does not interfere with sleep' and 10 represents 'completely interferes' which means you are unable to sleep due to pain.

    Time frame: Week 5 and Week 10

  7. Change From Baseline in Hospital Anxiety and Depression Scale (HADS-A) Anxiety Scores at Week 5 (Visit 4) and Week 10 (Visit 6)

    The HADS is a self-administered questionnaire measuring anxiety. Each subscale consists of 7 statements and the participants respond as to how each item applies to them on a scale of 0 to 3 (0 = No anxiety, to 3 = Severe feelings of anxiety). Separate scores are calculated for each subscale and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score the more severe the anxiety.

    Time frame: Week 5 and Week 10

  8. Change From Baseline in Hospital Anxiety and Depression Scale (HADS-D) Depression Scores at Week 5 (Visit 4) and Week 10 (Visit 6)

    The HADS is a self-administered questionnaire measuring depression. Each subscale consists of 7 statements and the participants respond as to how each item applies to them on a scale of 0 to 3 (0 = No depression, to 3 = Severe feelings of depression). Separate scores are calculated for each subscale and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score the more severe the depression.

    Time frame: Week 5 and Week 10

  9. Percentage of Days in Mild, Moderate and Severe Pain at Period 1 and Period 2

    Period 1 indicates from Visit 2 (baseline) to Visit 4 (Week 5). Period 2 indicates from Visit 4 (Week 5) to Visit 6 (Week 10). A rating of 0 is considered no pain; 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain.

    Time frame: Period 1 and Period 2

  10. Change From Baseline in Brief Pain Inventory Short Form (BPI sf) - Pain Severity Index Score at Week 5 and Week 10

    BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the past 24 hours. The Pain severity domain: The BPI severity domain includes pain at its 'worst,' 'least,' 'average,' and 'now' (current pain) on 0-10 NRS scales and takes the mean of these 4 items. Scores range from 0 (no pain) to 10 (pain as bad as you can imagine), therefore higher scores indicate greater pain severity.

    Time frame: Week 5 and Week 10

  11. Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Sleep Disturbance Subscale at Week 5 and Week 10

    The MOS-Sleep Scale is a self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. With the exception of sleep adequacy, optimal sleep, and quantity, higher scores reflect greater impairment in the MOS-Sleep subscales. Sleep Disturbance: Range=0 to 100; higher scores indicate greater sleep disturbance. Negative changes indicate improvement.

    Time frame: Week 5 and Week 10

  12. Percentage of Participants With >= 30% Reduction From Baseline in the Weekly Mean Pain NRS Score at Week 5 and Week 10

    The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.

    Time frame: Week 5 and Week 10

  13. Percentage of Participants With >= 50% Reduction From Baseline in the Weekly Mean Pain NRS Score at Week 5 and Week 10

    The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.

    Time frame: Week 5 and Week 10

07

Results

Posted Sep 1, 2016
Limitations and caveats
The study was terminated as it had been determined that it was no longer operationally feasible to continue the trial. The study termination was not due to a safety issue or finding.

Participant flow

This study was conducted at 28 sites across 7 countries. From a total of 232 participants screened, 180 were randomized into Period 1 and 166 entered into Period 2.

Participant flow — Overall Study
MilestoneArm AArm B
Started8991
Completed8175
Not completed816
Withdrew: Adverse event46
Withdrew: Protocol violation33
Withdrew: Withdrawal by subject02
Withdrew: Insufficient clinical response12
Withdrew: Medication error without associated ae01
Withdrew: Lost to follow-up02

Outcome measures

PrimaryChange From Baseline in the Weekly Mean Pain Numeric Rating Scale (NRS) Score at Week 5 (ie, Visit 4) Compared Between the Two Study Arms

The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.

Time frame:
Baseline and Week 5
Reported as:
Mean · Units on a scale
Change From Baseline in the Weekly Mean Pain Numeric Rating Scale (NRS) Score at Week 5 (ie, Visit 4) Compared Between the Two Study Arms
Units on a scaleArm AArm B
Change From Baseline in the Weekly Mean Pain Numeric Rating Scale (NRS) Score at Week 5 (ie, Visit 4) Compared Between the Two Study Arms-2.18 ± 0.212-2.03 ± 0.212
Statistical analysis
  • Arm A vs Arm B · Mixed Models Analysis · p = 0.6012 · Ls mean difference: -0.15 · 95% CI -0.72 to 0.42
SecondaryChange in the Weekly Mean Pain NRS Score in Arm B, Compared Between Week 5 (Visit 4) and Week 10 (Visit 6).

The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.

Time frame:
Week 5 and Week 10
Reported as:
Least squares mean · Units on a scale
Change in the Weekly Mean Pain NRS Score in Arm B, Compared Between Week 5 (Visit 4) and Week 10 (Visit 6).
Units on a scaleArm B
Change in the Weekly Mean Pain NRS Score in Arm B, Compared Between Week 5 (Visit 4) and Week 10 (Visit 6).1.42 ± 0.204
Statistical analysis
  • Arm B · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): 1.42 · 95% CI 1.02 to 1.83
SecondaryChange From Baseline in the Weekly Mean Pain NRS Score at Week 10 (Visit 6) Compared Between the Two Study Arms

The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.

Time frame:
Baseline and Week 10
Reported as:
Least squares mean · Units on a scale
Change From Baseline in the Weekly Mean Pain NRS Score at Week 10 (Visit 6) Compared Between the Two Study Arms
Units on a scaleArm AArm B
Change From Baseline in the Weekly Mean Pain NRS Score at Week 10 (Visit 6) Compared Between the Two Study Arms-3.21 ± 0.262-3.45 ± 0.265
Statistical analysis
  • Arm A vs Arm B · Mixed Models Analysis · p = 0.5128 · Mean difference (final values): 0.24 · 95% CI -0.48 to 0.95
SecondaryChange From Baseline in Benefit, Satisfaction, and Willingness to Continue Measure Scores Compared Between Arms at Week 5 (Visit 4) and at Week 10 (Visit 6)

The BSW consists of 3, single-item measures designed to capture the participant's perception of the effect of treatment in terms of the relative benefit, their satisfaction, and their intention or willingness to continue on therapy. The BSW was administered by the investigator or designated site personnel in the local language as a standardized interview during the follow-up visits. The BSW can potentially be self-administered; however, this method of administration has not been tested. Participants completed this questionnaire at Visit 4 and Visit 6.

Time frame:
Week 5 and Week 10
Reported as:
Number · Percentage of participants
Change From Baseline in Benefit, Satisfaction, and Willingness to Continue Measure Scores Compared Between Arms at Week 5 (Visit 4) and at Week 10 (Visit 6)
Percentage of participantsArm AArm B
Benefit from Treatment - No benefit (Week 5)10.16.6
Benefit from Treatment - Little benefit (Week 5)22.529.7
Benefit from Treatment - Much benefit (Week 5)61.853.8
Satisfaction from Treatment - DVN (Week 5) - Yes78.784.6
Satisfaction from Treatment - DVN (Week 5) - No15.75.5
A Little Satisfied (Week 5)20.226.4
Very Satisfied (Week 5)58.458.2
A Little Dissatisfied (Week 5)12.44.4
Very Dissatisfied (Week 5)3.41.1
Willingness to Continue - DVN (Week 5) - Yes94.489.0
Willingness to Continue - DVN (Week 5) - No01.1
A Little Bit Willing (Week 5)5.64.4
Very Willing (Week 5)88.884.6
A Little Unwilling (Week 5)00
Very Unwilling (Week 5)01.1
Benefit from Treatment - No benefit (Week 10)4.53.3
Benefit from Treatment - Little benefit (Week 10)14.69.9
Benefit from Treatment - Much benefit (Week 10)71.970.3
Satisfaction from Treatment - DVN (Week 10) - Yes83.180.2
Satisfaction from Treatment - DVN (Week 10) - No7.93.3
A Little Satisfied (Week 10)9.011.0
Very Satisfied (Week 10)74.269.2
A Little Dissatisfied (Week 10)5.62.2
Very Dissatisfied (Week 10)2.21.1
Willingness to Continue - DVN (Week 10) - Yes88.881.3
Willingness to Continue - DVN (Week 10) - No2.22.2
A Little Bit Willing (Week 10)4.54.4
Very Willing (Week 10)84.376.9
A Little Unwilling (Week 10)00
Very Unwilling (Week 10)2.22.2
SecondaryPatient Global Impression of Change (PGIC) Compared Between Arms at Week 5 (Visit 4) and at Week 10 (Visit 6)

The PGIC is a single-item, self-rated instrument that measures change in the patient's overall status since starting study medication on a scale from 1 (very much improved) to 7 (very much worse), where lower scores indicate greater improvement. This scale was administered at Visit 4 and Visit 6.

Time frame:
Week 5 and Week 10
Reported as:
Mean · Units on a scale
Patient Global Impression of Change (PGIC) Compared Between Arms at Week 5 (Visit 4) and at Week 10 (Visit 6)
Units on a scaleArm AArm B
Week 5 (n=84, 82)2.69 ± 0.112.64 ± 0.11
Week 10 (n=81, 76)2.31 ± 0.102.11 ± 0.11
Statistical analysis
  • Arm A vs Arm B · Mixed Models Analysis · p = 0.7251 · Ls mean difference: 0.05 · 95% CI -0.22 to 0.32
  • Arm A vs Arm B · Mixed Models Analysis · p = 0.1255 · Ls mean difference: 0.20 · 95% CI -0.06 to 0.46
SecondaryPercentage of Participants With PGIC for Each Arm Compared at Week 5 (Visit 4) and at Week 10 (Visit 6)

The PGIC is a single-item, self-rated instrument that measures change in the patient's overall status since starting study medication on a scale from 1 (very much improved) to 7 (very much worse), where lower scores indicate greater improvement. This scale was administered at Visit 4 and Visit 6.

Time frame:
Week 5 and Week 10
Reported as:
Number · percentage of participants
Percentage of Participants With PGIC for Each Arm Compared at Week 5 (Visit 4) and at Week 10 (Visit 6)
percentage of participantsArm AArm B
Week 5 - very much improved(n=84, 82)11.912.2
Week 5 - much worse(n=84, 82)44.043.9
Week 5 - much improved(n=84, 82)31.032.9
Week 5 - minimally improved(n=84, 82)8.39.8
Week 5 - no change(n=84, 82)4.81.2
Week 5 - minimally worse(n=84, 82)0.00.0
Week 5 - very much worse(n=84, 82)0.00.0
Week 5 - missing(n=84, 82)0.00.0
Week 10 - very much improved(n=81, 76)25.931.6
Week 10 - much improved(n=81, 76)46.951.3
Week 10 - minimally improved(n=81, 76)21.015.8
Week 10 - no change(n=81, 76)4.90.0
Week 10 - minimally worse(n=81, 76)0.01.3
Week 10 - much worse(n=81, 76)1.20.0
Week 10 - very much worse(n=81, 76)0.00.0
Week 10 - missing(n=81, 76)0.00.0
SecondaryChange From Baseline in Weekly Mean of Daily Sleep Interference Rating Scale (SIRS) Compared Between Arms at Week 5 (Visit 4) and at Week 10 (Visit 6)

The Daily Sleep Interference Rating Scale (SIRS) consists of an 11-point NRS ranging from 0 ("pain does not interfere with sleep") to 10 ("pain completely interferes with sleep" \[unable to sleep due to pain\]). Participants described how pain had interfered with their sleep during the past 24 hours: Select the number that best describes how your pain has interfered with your sleep during the past 24 hours on a scale from 0 to 10 where 0 represents 'does not interfere with sleep' and 10 represents 'completely interferes' which means you are unable to sleep due to pain.

Time frame:
Week 5 and Week 10
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Weekly Mean of Daily Sleep Interference Rating Scale (SIRS) Compared Between Arms at Week 5 (Visit 4) and at Week 10 (Visit 6)
Units on a scaleArm AArm B
Week 5(n= 85, 79)-2.46 ± 0.235-2.12 ± 0.236
Week 10(n=81, 75)-3.69 ± 0.265-3.38 ± 0.268
Statistical analysis
  • Arm A vs Arm B · Mixed Models Analysis · p = 0.2856 · Ls mean difference: -0.34 · 95% CI -0.97 to 0.29
  • Arm A vs Arm B · Mixed Models Analysis · p = 0.3987 · Ls mean difference: -0.31 · 95% CI -1.02 to 0.41
SecondaryChange From Baseline in Hospital Anxiety and Depression Scale (HADS-A) Anxiety Scores at Week 5 (Visit 4) and Week 10 (Visit 6)

The HADS is a self-administered questionnaire measuring anxiety. Each subscale consists of 7 statements and the participants respond as to how each item applies to them on a scale of 0 to 3 (0 = No anxiety, to 3 = Severe feelings of anxiety). Separate scores are calculated for each subscale and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score the more severe the anxiety.

Time frame:
Week 5 and Week 10
Reported as:
Mean · Units on a scale
Change From Baseline in Hospital Anxiety and Depression Scale (HADS-A) Anxiety Scores at Week 5 (Visit 4) and Week 10 (Visit 6)
Units on a scaleArm AArm B
Week 5 (n=84, 82)-2.23 ± 3.78-1.91 ± 3.23
Week 10 (n=81, 76)-3.09 ± 4.34-2.68 ± 4.08
SecondaryChange From Baseline in Hospital Anxiety and Depression Scale (HADS-D) Depression Scores at Week 5 (Visit 4) and Week 10 (Visit 6)

The HADS is a self-administered questionnaire measuring depression. Each subscale consists of 7 statements and the participants respond as to how each item applies to them on a scale of 0 to 3 (0 = No depression, to 3 = Severe feelings of depression). Separate scores are calculated for each subscale and a score (ranging from 0 to 21) is obtained for each subscale. The higher the score the more severe the depression.

Time frame:
Week 5 and Week 10
Reported as:
Mean · Units on a scale
Change From Baseline in Hospital Anxiety and Depression Scale (HADS-D) Depression Scores at Week 5 (Visit 4) and Week 10 (Visit 6)
Units on a scaleArm AArm B
Week 5 (n=84, 82)-1.87 ± 4.18-1.35 ± 3.87
Week 10 (n=81, 76)-2.57 ± 4.62-2.01 ± 3.84
SecondaryPercentage of Days in Mild, Moderate and Severe Pain at Period 1 and Period 2

Period 1 indicates from Visit 2 (baseline) to Visit 4 (Week 5). Period 2 indicates from Visit 4 (Week 5) to Visit 6 (Week 10). A rating of 0 is considered no pain; 1-3 is considered mild pain; 4-6, moderate pain; and 7-10, severe pain.

Time frame:
Period 1 and Period 2
Reported as:
Mean · % of days
Percentage of Days in Mild, Moderate and Severe Pain at Period 1 and Period 2
% of daysArm AArm B
Period 1 (n=88, 90) (Mild)19.1 ± 27.8815.3 ± 28.13
Period 2 (n=84, 81) (Mild)33.5 ± 36.9825.0 ± 34.50
Period 1 (n=88, 90) (Moderate)40.2 ± 34.0737.6 ± 35.23
Period 2 (n=84, 81) (Moderate)33.2 ± 34.2844.2 ± 39.41
Period 1 (n=88, 90) (Severe)38.8 ± 40.1144.8 ± 40.76
Period 2 (n=84, 81) (Severe)26.5 ± 39.0921.8 ± 34.91
SecondaryChange From Baseline in Brief Pain Inventory Short Form (BPI sf) - Pain Severity Index Score at Week 5 and Week 10

BPI-sf is a self-administered questionnaire developed to assess the severity of pain and the impact of pain on daily functions during the past 24 hours. The Pain severity domain: The BPI severity domain includes pain at its 'worst,' 'least,' 'average,' and 'now' (current pain) on 0-10 NRS scales and takes the mean of these 4 items. Scores range from 0 (no pain) to 10 (pain as bad as you can imagine), therefore higher scores indicate greater pain severity.

Time frame:
Week 5 and Week 10
Reported as:
Mean · Units on a scale
Change From Baseline in Brief Pain Inventory Short Form (BPI sf) - Pain Severity Index Score at Week 5 and Week 10
Units on a scaleArm AArm B
Week 5 (n=84, 82)-1.75 ± 2.07-1.68 ± 1.86
Week 10 (n=81, 76)-2.83 ± 2.26-2.99 ± 2.45
SecondaryChange From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Sleep Disturbance Subscale at Week 5 and Week 10

The MOS-Sleep Scale is a self-administered questionnaire consisting of 12 items that assess key constructs of sleep. Instrument scoring yields 7 subscales (sleep disturbance, snoring, awaken short of breath or with a headache, quantity of sleep, optimal sleep, sleep adequacy, and somnolence) as well as a 9-item overall sleep problems index. With the exception of sleep adequacy, optimal sleep, and quantity, higher scores reflect greater impairment in the MOS-Sleep subscales. Sleep Disturbance: Range=0 to 100; higher scores indicate greater sleep disturbance. Negative changes indicate improvement.

Time frame:
Week 5 and Week 10
Reported as:
Mean · Units on a scale
Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Sleep Disturbance Subscale at Week 5 and Week 10
Units on a scaleArm AArm B
Week 5 (n= 84, 82)-21.3 ± 29.73-16.5 ± 25.92
Week 10 (n= 81, 76)-27.1 ± 25.70-22.8 ± 25.04
SecondaryPercentage of Participants With >= 30% Reduction From Baseline in the Weekly Mean Pain NRS Score at Week 5 and Week 10

The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.

Time frame:
Week 5 and Week 10
Reported as:
Number · Percentage of participants
Percentage of Participants With >= 30% Reduction From Baseline in the Weekly Mean Pain NRS Score at Week 5 and Week 10
Percentage of participantsArm AArm B
Yes (Week 5)51.135.6
No (Week 5)48.964.4
Yes (Week 10)63.658.9
No (Week 10)31.831.1
SecondaryPercentage of Participants With >= 50% Reduction From Baseline in the Weekly Mean Pain NRS Score at Week 5 and Week 10

The Daily Pain diary consists of an 11-point NRS ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants described their pain during the past 24 hours by choosing the appropriate number between 0 and 10: Select the number that best describes your pain during the past 24 hours from 0 to10 where 0 represents no pain and 10 represents the worst possible pain.

Time frame:
Week 5 and Week 10
Reported as:
Number · Percentage of participants
Percentage of Participants With >= 50% Reduction From Baseline in the Weekly Mean Pain NRS Score at Week 5 and Week 10
Percentage of participantsArm AArm B
Yes (Week 5)25.020.0
No (Week 5)75.080.0
Yes (Week 10)42.037.8
No (Week 10)53.452.2

Adverse events

Collected over Adverse events were reported from the signing of the informed consent throughout the study period including 28 calendar days after the last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A—0/89 (0%)28/89 (31.5%)
Arm B—2/91 (2.2%)19/91 (20.9%)
Most frequent serious events
Most frequent serious events
EventArm AArm B
Back painMusculoskeletal and connective tissue disorders0/892/91
Most frequent other events
Most frequent other events
EventArm AArm B
DizzinessNervous system disorders12/8912/91
SomnolenceNervous system disorders12/897/91
HeadacheNervous system disorders10/897/91

Baseline characteristics

Safety population was composed of all participants who took at least one dose of study medication (either pregabalin or celecoxib).

Age, Continuous
Age, Continuous(Years)Arm AArm BTotal
Mean49.7 ± 11.749.2 ± 12.249.5 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Arm AArm BTotal
Female6563128
Male242852
08

Study locations

30 sites
  • Centro de Pesquisa Clínica do Hospital Universitário da Universidade Federal do Maranhão - CEPEC
    São Luís, Maranhão 65020-600, Brazil
  • Santa Casa de Misericórdia de Belo Horizonte
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • CMIP-Centro Mineiro de Pesquisa
    Juiz de Fora, Minas Gerais 36010-570, Brazil
  • EDUMED Educação em Saúde - Centro de Pesquisas Clínicas
    Curitiba, Paraná 80440-080, Brazil
  • Instituto Paulista de Reumatologia da UNIFESP
    São Paulo, SP 04026-000, Brazil
  • Faculdade de Medicina do ABC
    Santo André, SÃO Paulo 09060-650, Brazil
  • Instituto Paulista de Reumatologia da UNIFESP
    Sao Paulo, SÃO Paulo 04026-000, Brazil
  • Instituto de Pesquisa Clinica e Medicina Avancada - IMA Brasil
    Sao Paulo, 05437-010, Brazil
  • Centro de Diagnostico y Tratamiento Ltd. Clinica Siresa
    Temuco, Araucania, Chile
  • Centro de Investigación Clínica Neuropsicología Ltda
    La Florida, Santiago, Chile
  • Fundacion Cardiovascular de Colombia - Instituto del Corazon Floridablanca
    Floridablanca, Santander, Colombia
  • Centro Medico Imbanaco C.M.I (Sede 01 and Sede 02) / Sede 12 Centro Medico Imbanaco de Cali S.A.
    Santiago de Cali, Colombia
  • Hospital Raja Permaisuri Bainun
    Ipoh, Perak 30990, Malaysia
  • Hospital Seberang Jaya
    Seberang Jaya, Pulau Pinang 13700, Malaysia
  • Hospital Umum Sarawak (Sarawak General Hospital)
    Kuching, Sarawak 93586, Malaysia
  • Hospital Selayang
    Batu Caves, Selangor 68100, Malaysia
  • MENTRIALS S. A. de C. V.
    Mexico, DF 06700, Mexico
  • Centro Integral en Reumatología SA de CV
    Guadalajara, Jalisco 44160, Mexico
  • Clinica De Investigacion En Reumatologia Y Obesidad S.C.
    Guadalajara, Jalisco 44650, Mexico
  • Centro de Estudios de Investigacion Basica y Clinica SC.
    Guadalajara, Jalisco 44690, Mexico
  • Hospital Angeles Chapalita
    Guadalajara, Jalisco 45040, Mexico
  • Unidad de Cancerología
    Zapopan, Jalisco 45050, Mexico
  • Accelerium S. de R.L de C.V.
    Monterrey, Nuevo LEON 64000, Mexico
  • Unidad de Atención Médica e Investigacion en salud
    Merida, Yucatan 97000, Mexico
  • Unidad de Atencion Medica e Investigación en salud SC
    Merida, Yucatán 97130, Mexico
  • Centro de Investigacion y Atencion Integral de Durango SC
    Durango, 34080, Mexico
  • Raffles Hospital
    Singapore, 188770, Singapore
  • Maharaj Nakorn ChiangMai Hospital
    Muang, Chiang MAI 50200, Thailand
  • Sappasithiprasong Hospital
    Muang, Ubonratchathani Thailand 34000, Thailand
  • Division of Neurology ,
    Bangkok, 10400, Thailand
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of May 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2013
First posted
Apr 23, 2013
Start
Oct 2013
Primary completionActual
May 2015
CompletionActual
Jun 2015
Results first posted
Sep 1, 2016
Last update
Jan 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01838044
Responsible party
Sponsor
First posted
Apr 23, 2013
Start date
Oct 2013
Primary completion
May 2015
Completion
Jun 2015
Results posted
Sep 1, 2016
Last update
Jan 28, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pregabalin · Celecoxib

Start the discussion